GAMIDA CELL LTD.
|
||
May 7, 2019
|
By:
|
/s/ Shai Lankry
|
Shai Lankry
|
||
Chief Financial Officer
|
Exhibit
No.
|
Description
|
|
Unaudited Interim Consolidated Statements of Financial Position as of March 31, 2019 and March 31, 2018, and Unaudited Interim Consolidated
Statements of Comprehensive Loss, Statements of Changes in Shareholders’ Equity and Statements of Cash Flows for the three months ended March 31, 2019 and March
31, 2018
|
||
Management’s Discussion and Analysis of Financial Condition
and Results of Operations
|
||
Press Release, dated May 7, 2019 Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update
|
Page
|
|
Review of Interim Consolidated Financial Statements
|
2
|
Interim Consolidated Statements of Financial Position
|
3 - 4
|
Interim Consolidated Statements of Comprehensive Loss
|
5
|
Interim Consolidated Statements of Changes in Equity
|
6 – 7
|
Interim Consolidated Statements of Cash Flows
|
8 – 9
|
Notes to Interim Consolidated Financial Statements
|
10 - 16
|
Tel-Aviv, Israel
|
KOST FORER GABBAY & KASIERER
|
May 6, 2019
|
A Member of Ernst & Young Global
|
March 31,
|
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
ASSETS
|
||||||||||||
CURRENT ASSETS:
|
||||||||||||
Cash and cash equivalents
|
$
|
43,749
|
$
|
25,931
|
$
|
40,272
|
||||||
Available-for-sale financial assets
|
6,507
|
9,679
|
20,417
|
|||||||||
Prepaid expenses and other current assets
|
684
|
887
|
1,502
|
|||||||||
Total current assets
|
50,940
|
36,497
|
62,191
|
|||||||||
NON-CURRENT ASSETS:
|
||||||||||||
Property and equipment, net
|
2,782
|
1,122
|
2,311
|
|||||||||
Right-of-use assets
|
6,668
|
-
|
-
|
|||||||||
Other assets
|
657
|
355
|
662
|
|||||||||
Total non-current assets
|
10,107
|
1,477
|
2,973
|
|||||||||
Total assets
|
$
|
61,047
|
$
|
37,974
|
$
|
65,164
|
March 31,
|
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
LIABILITIES AND EQUITY
|
||||||||||||
CURRENT LIABILITIES:
|
||||||||||||
Trade payables
|
$
|
1,341
|
$
|
852
|
$
|
1,985
|
||||||
Employees and payroll accruals
|
2,580
|
-
|
2,888
|
|||||||||
Current maturities of lease liabilities
|
2,156
|
-
|
-
|
|||||||||
Accrued expenses and other payables
|
1,739
|
2,446
|
1,832
|
|||||||||
Total current liabilities
|
7,816
|
3,298
|
6,705
|
|||||||||
NON-CURRENT LIABILITIES:
|
||||||||||||
Liabilities presented at fair value
|
25,031
|
10,700
|
24,049
|
|||||||||
Employee benefit liabilities, net
|
276
|
184
|
183
|
|||||||||
Lease Liabilities
|
4,671
|
-
|
-
|
|||||||||
Liability to Israel Innovation Authority (IIA)
|
10,108
|
7,432
|
9,540
|
|||||||||
Total non-current liabilities
|
40,086
|
18,316
|
33,772
|
|||||||||
SHAREHOLDERS' EQUITY:
|
||||||||||||
Share capital -
|
||||||||||||
Ordinary shares of NIS 0.01 par value - Authorized: 100,000,000 shares at March 31, 2019 (unaudited) and December 31,
2018 and 23,277,000 shares at March 31,2018 (unaudited); Issued and outstanding: 25,140,048 and 24,930,736 shares at March 31, 2019 (unaudited) and December 31, 2018
respectivly, and 689,898 shares at March 31, 2018 (unaudited);
|
68
|
2
|
67
|
|||||||||
Preferred shares of NIS 0.01 par value - Authorized: 0 shares at March 31, 2019 (unaudited) and December 31, 2018 and 16,723,000 shares at March 31, 2018 (unaudited); Issued and outstanding: 0 shares at March 31, 2019 (unaudited) and December 31, 2018 and 14,154,743 shares at March 31, 2018 (unaudited);
|
-
|
38
|
-
|
|||||||||
Share premium
|
197,967
|
140,155
|
193,953
|
|||||||||
Capital reserve due to actuarial gains
|
(160
|
)
|
(79
|
)
|
(77
|
)
|
||||||
Available-for-sale reserve
|
(10
|
)
|
(83
|
)
|
(43
|
)
|
||||||
Accumulated deficit
|
(184,720
|
)
|
(123,673
|
)
|
(169,213
|
)
|
||||||
Total shareholders' equity
|
13,145
|
16,360
|
24,687
|
|||||||||
Total liabilities and shareholders' equity
|
$
|
61,047
|
$
|
37,974
|
$
|
65,164
|
May 6, 2019
|
||||
Date of approval of the
|
Julian Adams
|
Shai Lankry
|
||
financial statements
|
Director and CEO
|
Chief Financial Officer
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
Operating expenses:
|
||||||||||||
Research and development, net
|
$
|
7,283
|
$
|
5,060
|
$
|
22,045
|
||||||
General and administrative
|
3,813
|
1,653
|
11,599
|
|||||||||
Operating loss
|
11,096
|
6,713
|
33,644
|
|||||||||
Finance expenses
|
4,734
|
974
|
20,259
|
|||||||||
Finance income
|
(349
|
)
|
(296
|
)
|
(1,042
|
)
|
||||||
Loss before taxes on income
|
15,481
|
7,391
|
52,861
|
|||||||||
Taxes on income
|
26
|
-
|
70
|
|||||||||
Net loss
|
15,507
|
7,391
|
52,931
|
|||||||||
Other comprehensive loss:
|
||||||||||||
Items that will be reclassified subsequently to profit or loss:
|
||||||||||||
Actuarial net loss of defined benefit plans
|
83
|
-
|
(2
|
)
|
||||||||
Changes in the fair value of available for sale financial assets
|
(33
|
)
|
49
|
9
|
||||||||
Total comprehensive loss
|
15,557
|
7,440
|
52,938
|
|||||||||
Net loss per share:
|
||||||||||||
Basic and diluted net loss per share
|
0.62
|
10.78
|
10.53
|
|||||||||
Weighted average number of ordinary shares used in computing basic and diluted net loss per share
|
25,038,261
|
689,898
|
5,025,213
|
Ordinary shares
|
Preferred shares
|
Share
|
Available for
sale
reserve
|
Capital
reserve due
to actuarial
|
Accumulated
|
Total
|
||||||||||||||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Premium
|
Amount
|
losses
|
deficit
|
equity
|
||||||||||||||||||||||||||||
Balance as of January 1, 2019
|
24,930,736
|
$
|
67
|
-
|
$
|
-
|
$
|
193,953
|
$
|
(43
|
)
|
$
|
(77
|
)
|
$
|
(169,213
|
)
|
$
|
24,687
|
|||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(15,507
|
)
|
(15,507
|
)
|
|||||||||||||||||||||||||
Other comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
33
|
(83
|
)
|
-
|
(50
|
)
|
|||||||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
33
|
(83
|
)
|
(15,507
|
)
|
(15,557
|
)
|
||||||||||||||||||||||||
Exercise of warrants
|
209,312
|
1
|
-
|
-
|
2,923
|
-
|
-
|
-
|
2,924
|
|||||||||||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
-
|
1,091
|
-
|
-
|
-
|
1,091
|
|||||||||||||||||||||||||||
Balance as of March 31, 2019 (unaudited)
|
25,140,048
|
$
|
68
|
-
|
$
|
-
|
$
|
197,967
|
$
|
(10
|
)
|
$
|
(160
|
)
|
$
|
(184,720
|
)
|
$
|
13,145
|
Ordinary shares
|
Preferred shares
|
Share
|
Available for
sale
reserve
|
Capital
reserve due
to actuarial
|
Accumulated
|
Total
|
||||||||||||||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Premium
|
Amount
|
losses
|
deficit
|
equity
|
||||||||||||||||||||||||||||
Balance as of January 1, 2018
|
689,898
|
$
|
2
|
14,154,743
|
$
|
38
|
$
|
139,311
|
$
|
(34
|
)
|
$
|
(79
|
)
|
$
|
(116,282
|
)
|
$
|
22,956
|
|||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(7,391
|
)
|
(7,391
|
)
|
|||||||||||||||||||||||||
Other comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
(49
|
)
|
-
|
-
|
(49
|
)
|
|||||||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
(49
|
)
|
-
|
(7,391
|
)
|
(7,440
|
)
|
||||||||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
-
|
844
|
-
|
-
|
-
|
844
|
|||||||||||||||||||||||||||
Balance as of March 31, 2018 (unaudited)
|
689,898
|
$
|
2
|
14,154,743
|
$
|
38
|
$
|
140,155
|
$
|
(83
|
)
|
$
|
(79
|
)
|
$
|
(123,673
|
)
|
16,360
|
Ordinary shares
|
Preferred shares
|
Share
|
Available for
sale
reserve
|
Capital
reserve due to
actuarial
|
Accumulated
|
Total
|
||||||||||||||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Premium
|
Amount
|
losses
|
deficit
|
equity
|
||||||||||||||||||||||||||||
Balance as of January 1, 2018
|
689,898
|
$
|
2
|
14,154,743
|
$
|
38
|
139,311
|
$
|
(34
|
)
|
$
|
(79
|
)
|
$
|
(116,282
|
)
|
$
|
22,956
|
||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(52,931
|
)
|
(52,931
|
)
|
|||||||||||||||||||||||||
Other comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
(9
|
)
|
2
|
-
|
(7
|
)
|
|||||||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
-
|
-
|
-
|
(9
|
)
|
2
|
(52,931
|
)
|
(52,938
|
)
|
||||||||||||||||||||||||
Issuance of additional preferred shares following Anti-dilution Protection
|
-
|
-
|
3,134,546
|
8
|
(8
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||||
Exercise of options
|
9,692
|
-
|
-
|
-
|
2
|
-
|
-
|
-
|
2
|
|||||||||||||||||||||||||||
Conversion of preferred shares
|
17,289,289
|
46
|
(17,289,289
|
)
|
(46
|
)
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||||||||||||
Issuance of ordinary shares in initial public offering, net of issuance expenses in an amount of $5,947
|
6,648,368
|
18
|
-
|
-
|
47,223
|
-
|
-
|
-
|
47,241
|
|||||||||||||||||||||||||||
Exercise of warrants
|
293,489
|
1
|
-
|
-
|
3,850
|
-
|
-
|
-
|
3,851
|
|||||||||||||||||||||||||||
Share-based compensation
|
-
|
-
|
-
|
-
|
3,575
|
-
|
-
|
-
|
3,575
|
|||||||||||||||||||||||||||
Balance as of December 31, 2018
|
24,930,736
|
$
|
67
|
-
|
$
|
-
|
193,953
|
$
|
(43
|
)
|
$
|
(77
|
)
|
$
|
(169,213
|
)
|
$
|
24,687
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
Cash flows from operating activities:
|
||||||||||||
Net loss
|
$
|
(15,507
|
)
|
$
|
(7,391
|
)
|
$
|
(52,931
|
)
|
|||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
Adjustments to the profit or loss items:
|
||||||||||||
Depreciation of property, plant and equipment and right-of-use assets
|
542
|
49
|
269
|
|||||||||
Financial income, net
|
(191
|
)
|
-
|
(858
|
)
|
|||||||
Cost of share-based compensation
|
1,091
|
844
|
3,575
|
|||||||||
Change in employee benefit liabilities, net
|
11
|
(16
|
)
|
(15
|
)
|
|||||||
Interest received
|
-
|
(13
|
)
|
-
|
||||||||
Amortization of premium on available-for-sale financial asses
|
50
|
81
|
272
|
|||||||||
Revaluation of financial derivatives
|
3,907
|
400
|
17,600
|
|||||||||
Revaluation of liability to IIA
|
568
|
412
|
2,037
|
|||||||||
5,978
|
1,757
|
22,880
|
||||||||||
Changes in asset and liability items:
|
||||||||||||
Increase in prepaid expenses and other current assets and other assets
|
409
|
100
|
942
|
|||||||||
Decrease in trade payables
|
(844
|
)
|
(1,538
|
)
|
(405
|
)
|
||||||
Increase - in accrued expenses and other payables
|
21
|
260
|
2,296
|
|||||||||
(414
|
)
|
(1,178
|
)
|
2,833
|
||||||||
Cash received during the period for:
|
||||||||||||
Interest received
|
521
|
13
|
792
|
|||||||||
Interest paid
|
(28
|
)
|
-
|
-
|
||||||||
Net cash used in operating activities
|
(9,450
|
)
|
(6,799
|
)
|
(26,426
|
)
|
||||||
Cash flows from investing activities:
|
||||||||||||
Purchase of property and equipment
|
(350
|
)
|
(231
|
)
|
(1,645
|
)
|
||||||
Purchase of of available-for-sale financial assets
|
-
|
-
|
(10,905
|
)
|
||||||||
Proceed from sale of available-for-sale financial assets
|
13,893
|
4,984
|
4,949
|
|||||||||
Proceeds from bank deposits
|
-
|
5,000
|
5,000
|
|||||||||
Investment in restricted bank deposits
|
-
|
-
|
(150
|
)
|
||||||||
Net cash provided by (used in) investing activities
|
|
13,543
|
9,753
|
(2,751
|
)
|
Three months ended
March 31
|
Year ended
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
Cash flows from financing activities:
|
||||||||||||
Receipt of grants from the IIA
|
|
-
|
|
1,652
|
|
612
|
||||||
Proceeds from initial public offering, net
|
(238
|
)
|
-
|
47,479
|
||||||||
Payment of lease liabilities
|
(440
|
)
|
-
|
-
|
||||||||
Exercise of options
|
-
|
-
|
2
|
|||||||||
Net cash (used in) provided by financing activities
|
(678
|
)
|
1,652
|
48,093
|
||||||||
Exchange differences on balances of cash and cash equivalents
|
62
|
-
|
31
|
|||||||||
Increase in cash and cash equivalents
|
3,477
|
4,606
|
18,947
|
|||||||||
Cash and cash equivalents at beginning of period
|
40,272
|
21,325
|
21,325
|
|||||||||
Cash and cash equivalents at end of period
|
$
|
43,749
|
$
|
25,931
|
$
|
40,272
|
||||||
Supplemental disclosure of non-cash financing activities:
|
||||||||||||
Significant non-cash transactions:
|
||||||||||||
IIA liability for grants to be received
|
$
|
-
|
$
|
130
|
$
|
-
|
||||||
Exercise of warrants liabilities to equity
|
$
|
2,924
|
$
|
-
|
$
|
3,851
|
||||||
Purchase of property, plant and equipment on credit
|
$
|
199
|
$
|
-
|
$
|
-
|
||||||
Issuance expenses on credit
|
$
|
-
|
$
|
-
|
$
|
238
|
NOTE 1:-
|
GENERAL
|
a.
|
Gamida Cell Ltd. (the "Company"), founded in 1998, is a clinical-stage biopharmaceutical company that develops novel curative treatments for orphan indications,
including hematologicalmalignancies and rare genetic diseases using stem cells and Natural Killer (NK) cells.
|
b. |
The Company uses its proprietary platform NAM technology to expand in culture, highly functional cells derived from umbilical cord blood or peripheral blood, while
enhancing the potential therapeutic efficacy of these cells.
|
c. |
The Company is devoting substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating
losses and expects such losses to continue in the foreseeable future. The Company's accumulated deficit as of March 31, 2019 is $184,720 and negative cash flows from operating activities during the period is $9,450. These conditions
raise substantial doubt about the Company's ability to continue as a going concern. The interim consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that
would result if the Company was unable to continue as a going concern. The Company requires additional financing in order to continue to fund its current operations and pay existing and future liabilities.
|
NOTE 1:- |
GENERAL (Cont.)
|
d.
|
Definitions:
|
The Company
|
-
|
Gamida Cell Ltd. and its subsidiary
|
|
Subsidiary
|
Gamida Cell Inc. Incorporated in 2000 and intended to focus on sales and marketing upon product approval.
|
||
Related Parties
|
-
|
As defined in IAS 24
|
|
Dollar
|
-
|
U.S. dollar
|
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES
|
a. |
The accompanying unaudited interim consolidated financial statements for the three months periods ended March 31, 2019 and 2018 have been prepared in accordance with IAS 34
"Interim Financial Reporting" for interim financial information.
|
b. |
The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the company's
annual consolidated financial statements for the year ended December 31, 2018, except for the adoption of new standards effective as of January 1, 2019. The Company has not early adopted any other standard, interpretation or amendment
that has been issued but is not yet effective.
|
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.)
|
c. |
IFRS 16 Leases:
|
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.)
|
• |
Right-of-use assets of $7,106 were recognized and presented separately in the statement of financial position.
|
• |
Additional lease liabilities of $7,032 were recognized and presented separately in the statement of financial position .
|
• |
Prepaid expenses and other current assets of $256 and accrued expenses and other payables of $182 related to previous operating leases were derecognized.
|
Right-of-use assets
|
Lease liabilities
|
|||||||||||||||||||
Offices and labs
|
Vechicles
|
Production Plant
|
Total
|
|||||||||||||||||
As of January 1, 2019
|
$
|
2,104
|
$
|
291
|
$
|
4,711
|
$
|
7,106
|
$
|
7,032
|
||||||||||
Depreciation expenses
|
(292
|
)
|
(32
|
)
|
(140
|
)
|
(464
|
)
|
-
|
|||||||||||
Interest expenses
|
-
|
-
|
-
|
-
|
237
|
|||||||||||||||
Re-measurement
|
-
|
-
|
26
|
26
|
26
|
|||||||||||||||
Payments
|
-
|
-
|
-
|
-
|
(468
|
)
|
||||||||||||||
As of March 31, 2019
|
$
|
1,812
|
$
|
259
|
$
|
4,597
|
$
|
6,668
|
$
|
6,827
|
Operating lease commitments as of December 31, 2018
|
$
|
7,441
|
||
Weighted average incremental borrowing rate as of January 1, 2019 (%)
|
1.42
|
|||
Discounted operating lease commitments of January 1, 2019
|
7,032
|
|||
Lease liabilities as of January 1, 2019
|
$
|
7,032
|
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.)
|
a. |
Right-of-use assets
|
b. |
Lease liabilities
|
NOTE 3:- |
SHARE-BASED PAYMENT
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
||||||||||||
Research and development
|
$
|
229
|
$
|
482
|
$
|
705
|
||||||
General and administrative
|
862
|
362
|
2,870
|
|||||||||
$
|
1,091
|
$
|
844
|
$
|
3,575
|
NOTE 3:- |
SHARE-BASED PAYMENT (cont.)
|
Three months ended
March 31,
|
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Dividend yield (%)
|
0
|
0
|
0
|
|||||||||
Expected volatility of the share prices (%)
|
76%-80
|
%
|
88%-94
|
%
|
93%-95
|
%
|
||||||
Risk-free interest rate (%)
|
2.51-2.70
|
2.17-2.89
|
2.63-2.88
|
Three months ended
March 31,
|
Year ended
December 31,
|
|||||||||||||||||||||||
2019
|
2018
|
2018
|
||||||||||||||||||||||
Number of
options
|
Weighted
average
exercise
price
|
Number of
options
|
Weighted
average
exercise
price
|
Number of
options
|
Weighted
average
exercise
price
|
|||||||||||||||||||
USD
|
USD
|
USD
|
||||||||||||||||||||||
Outstanding at beginning of period
|
3,197,616
|
3.07
|
2,467,023
|
2.28
|
2,467,023
|
2.28
|
||||||||||||||||||
Granted during the period
|
544,800
|
10.93
|
-
|
-
|
751,977
|
5.60
|
||||||||||||||||||
Expired during the period
|
-
|
-
|
-
|
-
|
(2,000
|
)
|
6.00
|
|||||||||||||||||
Exercised during the period
|
-
|
-
|
-
|
-
|
(9,692
|
)
|
0.25
|
|||||||||||||||||
Forfeited during the period
|
-
|
-
|
(9,692
|
)
|
0.25
|
(9,692
|
)
|
0.25
|
||||||||||||||||
Share options outstanding at end of period
|
3,742,416
|
3.63
|
2,457,331
|
2.27
|
3,197,616
|
3.07
|
||||||||||||||||||
Share options exercisable at end of period
|
1,755,342
|
1.37
|
1,428,275
|
0.74
|
1,705,256
|
1.21
|
NOTE 4:- |
LIABILITIES PRESENTED AT FAIR VALUE
|
a.
|
Warrants to purchase Company's shares:
|
Three months ended
March 31,
|
December 31,
|
|||||||||||
2019
|
2018
|
2018
|
||||||||||
Unaudited
|
Audited
|
|||||||||||
Risk-free interest rate
|
2.21
|
%
|
2.3
|
%
|
2.52
|
%
|
||||||
Expected volatility
|
82
|
%
|
90
|
%
|
80
|
%
|
||||||
Expected life (in years)
|
3.25
|
2.25-3
|
3.5
|
|||||||||
Expected dividend yield
|
0
|
0
|
0
|
b. |
Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:
|
Fair value of
financial
derivatives
|
||||
Balance at December 31, 2018
|
$
|
24,048
|
||
Exercise of warrants
|
(2,924
|
)
|
||
Revaluation of financial derivatives
|
3,907
|
|||
Balance at March 31, 2019
|
$
|
25,031
|
• |
Omidubicel selected as nonproprietary name for NiCord: Today
Gamida Cell announced that the United States Adopted Names (USAN) Council selected omidubicel as the nonproprietary name for Gamida Cell’s investigational hematopoietic stem cell expanded through the company’s proprietary
nicotinamide-based, or NAM, technology. The USAN Council aims for global standardization and unification of drug nomenclature to ensure that drug information is communicated accurately and unambiguously. Gamida Cell’s lead
investigational product has two components: omidubicel (hematopoietic stem cells expanded through the company’s proprietary nicotinamide-based, or NAM, technology) and differentiated immune cells, including T cells. Gamida Cell refers
to the two components collectively as “omidubicel.” Going forward, Gamida Cell will use the name “omidubicel” in publications and public
statements, at conferences and other forums, and in medical and commercial-related materials.
|
• |
Reported encouraging data for omidubicel and GDA-201 at TCT Annual
Meeting: In February, data from the omidubicel and GDA-201 clinical programs were reported at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation and Center
for International Blood and Marrow Transplant. Research from the completed Phase 1/2 clinical study of omidubicel demonstrated that recipients who received omidubicel had rapid and robust reconstitution of key immune cells. Successful
immune reconstitution is an important factor in the recovery of patients undergoing bone marrow transplant.
|
• |
Evolved Board of Directors to reflect company’s progress toward
commercialization: In March, the company announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board
of directors. These nominations require approval at the Annual Shareholders Meeting, which will take place in June 2019. Ms. Tomasello has extensive experience in commercializing first-in-class medicines for the treatment of cancer,
including Yescarta® (at Kite Pharma, now part of Gilead Sciences) and Imbruvica® (at Pharmacyclics, now part of AbbVie). Mr. Wills has extensive operational, financial and transactional experience over nearly three
decades in the life sciences and accounting industries. He has served as chief financial officer of Palatin Technologies, a publicly-traded biotechnology company developing peptide therapeutics, since 1997 and also serves as Palatin’s
chief operating officer and executive vice president.
|
• |
Appointed Thomas Klima as chief commercial officer: In
January, the company announced the appointment of Thomas Klima as chief commercial officer. In this newly created role, Mr. Klima will be
responsible for building the team and executing the strategy to potentially bring omidubicel to patients, including oversight of reimbursement and patient services. Klima brings nearly 20 years of global experience in the pharmaceutical industry with expertise in cellular therapy, hematology, oncology and transplantation. During his career, he has played key roles in
building commercial organizations and leading multiple successful product launches.
|
• |
Initiate Cohort 2 in the Phase 1/2 study evaluating omidubicel as stand-alone graft in severe aplastic anemia in the first half of 2019
|
• |
Complete enrollment in Phase 3 study of omidubicel in patients with hematologic malignancies in the second half of 2019
|
• |
Report topline data from the Phase 3 study of omidubicel in patients with hematologic malignancies in the first half of 2020
|
• |
Complete BLA submission for omidubicel in hematologic malignancies in the second half of 2020, should Phase 3 data be positive
|
• |
Complete patient enrollment in the ongoing Phase 1 study in the second half of 2019
|
• |
Present additional data at a medical meeting in the second half of 2019
|
• |
Initiate multi-center, Phase 1/2 clinical study in patients with NHL in 2020
|
• |
As of March 31, 2019, Gamida Cell had total cash, cash equivalents and available-for-sale securities of $50.3 million, compared to $60.7 million as of December
31, 2018.
|
• |
Research and development expenses in the first quarter of 2019 were $7.3 million, compared to $5.1 million in the same period in 2018. The difference was
attributable mainly to a $1.2 million increase in clinical activities relate to the advancement of omidubicel and GDA-201, $0.5 million reduction in grants received from the Israeli Innovation Authority (IIA) and an increase of $0.5
million in compensation and other R&D expenses.
|
• |
General and administrative expenses were $3.8 million for the first quarter of 2019, compared to $1.7 million in the same period in 2018. The increase was due
mainly to a $1.0 million increase in expenses related to hiring and establishing the U.S. headquarters, an increase of $0.5 million in non-cash stock-based compensation expenses, and $0.6 million in professional services, rent and other
expenses.
|
• |
Finance expenses, net, were $4.4 million for the three months ended March 31, 2019, compared to $0.7 million in income in the same period in 2018. The increase
was primarily due to noncash expenses resulting from revaluation of warrants and the revaluation of royalty-bearing grant IIA liability.
|
• |
Net loss for the first quarter of 2019 was $15.5 million, compared to a net loss of $7.4 million in the same period in 2018.
|
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
|
||||||||
U.S. dollars in thousands
|
||||||||
March 31,
|
December 31,
|
|||||||
2019
|
2018
|
|||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
43,749
|
$
|
40,272
|
||||
Available-for-sale financial assets
|
6,507
|
20,417
|
||||||
Prepaid expenses and other current assets
|
684
|
1,502
|
||||||
Total current assets
|
50,940
|
62,191
|
||||||
NON-CURRENT ASSETS:
|
||||||||
Property and equipment, net
|
2,782
|
2,311
|
||||||
Right-of-use assets
|
6,668
|
-
|
||||||
Other assets
|
657
|
662
|
||||||
Total non-current assets
|
10,107
|
2,973
|
||||||
Total assets
|
$
|
61,047
|
$
|
65,164
|
||||
LIABILITIES AND EQUITY
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
1,341
|
$
|
1,985
|
||||
Employees and payroll accruals
|
2,580
|
2,888
|
||||||
Current maturities of lease liabilities
|
2,156
|
-
|
||||||
Accrued expenses and other payables
|
1,739
|
1,832
|
||||||
Total current liabilities
|
7,816
|
6,705
|
||||||
NON-CURRENT LIABILITIES:
|
||||||||
Liabilities presented at fair value
|
25,031
|
24,049
|
||||||
Employee benefit liabilities, net
|
276
|
183
|
||||||
Lease Liabilities
|
4,671
|
-
|
||||||
Liability to Israel Innovation Authority (IIA)
|
10,108
|
9,540
|
||||||
Total non-current liabilities
|
40,086
|
33,772
|
||||||
SHAREHOLDERS’ EQUITY:
|
||||||||
Share capital
|
68
|
67
|
||||||
Share premium
|
197,967
|
193,953
|
||||||
Capital reserve due to actuarial gains
|
(160
|
)
|
(77
|
)
|
||||
Available-for-sale reserve
|
(10
|
)
|
(43
|
)
|
||||
Accumulated deficit
|
(184,720
|
)
|
(169,213
|
)
|
||||
Total shareholders’ equity
|
13,145
|
24,687
|
||||||
Total liabilities and shareholders’ equity
|
$
|
61,047
|
$
|
65,164
|
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
||||||||
U.S. dollars in thousands (except share and per share data)
|
||||||||
Three months ended
|
||||||||
March 31,
|
||||||||
2019
|
2018
|
|||||||
Operating expenses:
|
||||||||
Research and development, net
|
$
|
7,283
|
$
|
5,060
|
||||
General and administrative
|
3,813
|
1,653
|
||||||
Operating loss
|
11,096
|
6,713
|
||||||
Finance expenses
|
4,734
|
974
|
||||||
Finance income
|
(349
|
)
|
(296
|
)
|
||||
Loss before taxes on income
|
15,481
|
7,391
|
||||||
Taxes on income
|
26
|
-
|
||||||
Net loss
|
15,507
|
7,391
|
||||||
Other comprehensive loss:
|
||||||||
Items that will be reclassified subsequently to profit or loss:
|
||||||||
Actuarial net loss of defined benefit plans
|
83
|
-
|
||||||
Changes in the fair value of available for sale financial assets
|
(33
|
)
|
49
|
|||||
Total comprehensive loss
|
15,557
|
7,440
|
||||||
Net loss per share:
|
||||||||
Basic and diluted net loss per share
|
0.62
|
10.78
|
||||||
Weighted average number of ordinary shares used in computing basic and diluted net loss per share
|
25,038,261
|
689,898
|
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||
U.S. dollars in thousands
|
||||||||
Three months ended
|
||||||||
March 31,
|
||||||||
2019
|
2018
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$
|
(15,507
|
)
|
$
|
(7,391
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Adjustments to the profit or loss items:
|
||||||||
Depreciation of property, plant and equipment and right-of-use assets
|
542
|
49
|
||||||
Financial income, net
|
(191
|
)
|
-
|
|||||
Cost of share-based compensation
|
1,091
|
844
|
||||||
Change in employee benefit liabilities, net
|
11
|
(16
|
)
|
|||||
Interest received
|
-
|
(13
|
)
|
|||||
Amortization of premium on available-for-sale financial asses
|
50
|
81
|
||||||
Revaluation of financial derivatives
|
3,907
|
400
|
||||||
Revaluation of liability to IIA
|
568
|
412
|
||||||
5,978
|
1,757
|
|||||||
Changes in asset and liability items:
|
||||||||
Increase in prepaid expenses and other current assets and other assets
|
409
|
100
|
||||||
Decrease in trade payables
|
(844
|
)
|
(1,538
|
)
|
||||
Increase - in accrued expenses and other payables
|
21
|
260
|
||||||
(414
|
)
|
(1,178
|
)
|
|||||
Cash received during the period for:
|
||||||||
Interest received
|
521
|
13
|
||||||
Interest paid
|
(28
|
)
|
-
|
|||||
Net cash used in operating activities
|
(9,450
|
)
|
(6,799
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
(350
|
)
|
(231
|
)
|
||||
Proceed from sale of available-for-sale financial assets
|
13,893
|
4,984
|
||||||
Proceeds from bank deposits
|
-
|
5,000
|
||||||
Net cash provided by investing activities
|
13,543
|
9,753
|
||||||
Cash flows from financing activities:
|
||||||||
Receipt of grants from the IIA
|
|
-
|
|
1,652
|
||||
Proceeds from initial public offering, net
|
(238
|
)
|
-
|
|||||
Payment of lease liabilities
|
(440
|
)
|
-
|
|||||
Net cash (used in) provided by financing activities
|
(678
|
)
|
1,652
|
|||||
Exchange differences on balances of cash and cash equivalents
|
62
|
-
|
||||||
Increase in cash and cash equivalents
|
3,477
|
4,606
|
||||||
Cash and cash equivalents at beginning of period
|
40,272
|
21,325
|
||||||
Cash and cash equivalents at end of period
|
$
|
43,749
|
$
|
25,931
|
||||
Supplemental disclosure of non-cash financing activities:
|
||||||||
Significant non-cash transactions:
|
||||||||
IIA liability for grants to be received
|
$
|
-
|
$
|
130
|
||||
Exercise of warrants liabilities to equity
|
$
|
2,924
|
$
|
-
|
||||
Purchase of property, plant and equipment on credit
|
$
|
199
|
$
|
-
|